

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1642
Examiner : Bansal, G
Serial No. :
Filed : Herewith
Inventors : Fabrice DuPrat



22469

: Florian LeSage
: Michel Fink
: Michel Lazdunski
Title : FAMILY OF MAMMALIAN
: POTASSIUM CHANNELS,
: THEIR CLONING AND THEIR USE,
: ESPECIALLY FOR THE SCREENING
: OF DRUGS

Docket: 1201-CIP-DIV-2-00

Dated: August 24 2001

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before calculation of the claims and action on the merits of the case, Applicants respectfully request that the claims be amended as follows:

Version with Markings Showing Changes to the Claims

29. (Amended) A transgenic animal which comprises an isolated and purified nucleic acid molecule coding for a protein having a potassium (K⁺) permeable membrane, comprising more than one P domains and three, four, five or more than six transmembrane segments [the nucleic acid sequence of claim 1] encoding a potassium transport channel.

33. (Amended) A pharmaceutical composition for the treatment of diseases caused by a defective potassium transport or a deficiency of the potassium transport protein comprising an isolated and purified nucleic acid molecule coding for a protein having a potassium (K⁺) permeable membrane, comprising more than one P domains and three, four, five or more than six transmembrane segments [the nucleic acid of claim 1] or a prokaryote or eukaryote cell with a self-replicating vector comprising said nucleic acid molecule [the

transformed cells of claim 25] in one or more tissues having a defective potassium transport function under conditions which allow for the expression of the potassium transport channel in said tissue.

Remarks

No new matter has been added. Applicants respectfully request an early and favorable action on the merits of the case.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC:rb
(215) 563-1810

Clean Version of the Claims

29. (Amended) A transgenic animal which comprises an isolated and purified nucleic acid molecule coding for a protein having a potassium (K⁺) permeable membrane, comprising more than one P domains and three, four, five or more than six transmembrane segments encoding a potassium transport channel.

33. (Amended) A pharmaceutical composition for the treatment of diseases caused by a defective potassium transport or a deficiency of the potassium transport protein comprising an isolated and purified nucleic acid molecule coding for a protein having a potassium (K⁺) permeable membrane, comprising more than one P domains and three, four, five or more than six transmembrane segments or a prokaryote or eukaryote cell with a self-replicating vector comprising said nucleic acid molecule in one or more tissues having a defective potassium transport function under conditions which allow for the expression of the potassium transport channel in said tissue.